Search for Clinical Trial Results

Monosomy - 7 Studies Found
Status | Study |
Completed |
Study Name: Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Condition:
Date: 2008-09-26 Interventions: Drug: lenalidomide Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increa |
Recruiting |
Study Name: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Condition: Acute Myeloid Leukemia Date: 2012-02-13 Interventions: Drug: sorafenib, vorinostat and bortezomib Escalating dose cohorts of sorafenib, vorinostat and bortezom |
Active, not recruiting |
Study Name: Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Condition: Leukemia Date: 2007-11-02 Interventions:
|
Terminated |
Study Name: Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Condition:
Date: 2008-07-17 Interventions: Drug: lenalidomide p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT |
Terminated |
Study Name: LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Condition: AML Date: 2010-07-29 Interventions: Drug: Lenalidomide Initial dose of oral lenalidomide is 10 |
Completed |
Study Name: A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Condition:
|
Terminated |
Study Name: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes Condition:
Date: 2009-06-17 Interventions:
|